Association between serum levels and pentanucleotide polymorphism in the sex hormone binding globulin gene and cardiovascular risk factors in females with polycystic ovary syndrome

Molecular Medicine Reports

Volumn 11, Issue 5, 2015, Pages 3941-3947

  Baldani, Dinka Pavicic ^a   Skrgatic, Lana ^a   Cerne, Jasmina Ziva ^b   Oguic, Sasa Kralik ^c   Gersak, Blaz Matija ^d   Gersak, Ksenija ^b,d  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c Zagreb Medical Center   (Croatia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

C reactive protein; Polycystic ovary syndrome; Sex hormone binding globulin; TAAAA repeat polymorphism

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; SEX HORMONE BINDING GLOBULIN; OLIGONUCLEOTIDE;

ADULT; ALLELE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MULTIPLE LINEAR REGRESSION ANALYSIS; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL; WAIST HIP RATIO; BLOOD; CASE CONTROL STUDY; GENETICS; METABOLISM; NUCLEOTIDE REPEAT; RISK FACTOR; YOUNG ADULT;

ADULT; ALLELES; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; OLIGONUCLEOTIDES; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, GENETIC; REPETITIVE SEQUENCES, NUCLEIC ACID; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; YOUNG ADULT;

EID: 84922308671     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.3117     Document Type: Article

References (37)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19: 41-47, 2004.
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81: 19-25, 2004.
3. Carmina E, Chu MC, Longo RA, Rini GB and Lobo RA: Phenotypic variation in hyperandrogenic women influences the finding of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 90: 2545-2549, 2005.
4. Boulman N, Levy Y, Leiba LR, Shachar S, et al: Increased C-reactive protein levels in polycystic ovary syndrome: a maker of cardiovascular disease. J Clin Endocrinol Metab 89: 2160-2165, 2004.
5. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M and Tapanainen JS: Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 4649-4654, 2003.
6. Escobar-Morreale HF, Luque-Ramírez M and González F: Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 95: 1048-1058, 2011.
7. Toulis KA, Goulis DG, Mintziori G, et al: Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 17: 741-760, 2011.
8. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH and van der Schouw YT: Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 40: 189-207, 2011.
9. Speroff L, Glass RH and Kase NG (eds): Anovulation and the polycystic ovary. In: Clinical Gynecologic Endocrinology and Infertility. Lippincott Wiliams &Wilkins, Philadelphia, USA, pp487-521, 1999.
10. Peter A, Kantartzis K, Machann J, et al: Relationships of circulating sex hormone-binding globulin with metabolic traits in humans. Diabetes 59: 3167-3173, 2010.
11. Liao CH, Li HY, Yu HJ, et al: Low serum sex hormone-binding globulin: marker of inflammation? Clin Chim Acta 413: 803-807, 2012.
12. Bonnet F, Balau B, Malécot JM, et al: Sex hormone-binding globulin predicts the incidence of hyperglycemia in women: interactions with adiponectin levels. Eur J Endocrinol 161: 81-85, 2009.
13. Ding EL, Song Y, Manson JE, et al: Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 361: 1152-1163, 2009.
14. Xita N and Tsatsoulis A: Genetic variants of sex hormone-binding globulin and their biological consequences. Mol Cell Endocrinol 316: 60-65, 2010.
15. Hogeveen KN, Talikka M and Hammond GL: Human sex hormone-binding globulin promoter activity is influenced by a (TAAAA)n repeat element within an Alu sequence. J Biol Chem 276: 36383-36390, 2001.
16. Xita N, Tsatsoulis A, Chatzikyriakidou A and Georgiou I: Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab 88: 5976-5980, 2003.
17. Ferk P, Teran N and Gersak K: The (TAAAA)n microsatellite polymorphism in the SHBG gene influences serum SHBG levels in women with polycystic ovary syndrome. Hum Reprod 22: 1031-1036, 2007.
18. Cousin P, Calemard-Michel L, Lejeune H, et al: Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women. J Clin Endocrinol Metab 89: 917-924, 2004.
19. Liu Q, Gu W, Cui B, et al: The association of TAAAAn repeat polymorphism in sex hormone-binding protein gene with polycystic ovary syndrome in Chinese population. Endocrine 34: 62-67, 2008.
20. Alevizaki M, Saltiki K, Xita N, et al: The importance of the (TAAAA)n alleles at the SHBG gene promoter for the severity of coronary artery disease in postmenopausal women. Menopause 15: 461-468, 2008.
21. Saltiki K, Stamatelopoulos K, Voidonikola P, et al: Association of the SHBG gene promoter polymorphism with early markers of atherosclerosis in apparently healthy women. Atherosclerosis 219: 205-210, 2011.
22. Ferriman D and Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21: 1440-1447, 1961.
23. Vermeulen A, Verdonck L and Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84: 3666-3672, 1999.
24. Friedewald WT, Levy RI and Fredericson DS: Estimation of the concentration of low density lipoprotein cholesterol without use of the ultracentrifuge. Clin Chem 18: 499-502, 1972.
25. Tsatsoulis A: Developmental programming of polycystic ovary syndrome: role of prenatal androgen excess. In: Tsatsoulis A, Wyckoff J, Brown FM (eds) Diabetes in Women: Pathophysiology and Therapy, Humana Press, New York, NY, pp83-103, 2009.
26. Baldani DP, Skrgatić L, Goldstajn MS et al: Clinical and biochemical characteristics of polycystic ovary syndrome in Croatian population. Coll Antropol 36: 1413-1418, 2012.
27. González F, Rote NS, Minium J and Kirwan JP: Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 91: 1508-1512, 2006.
28. González F, Rote NS, Minium J and Kirwan JP: Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 91: 336-340, 2006.
29. González F, Rote NS, Minium J and Kirwan JP: Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism 58: 954-962, 2009.
30. González F, Nair KS, Daniels JK, et al: Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. J Clin Endocrinol Metab 97: 2836-2843, 2012.
31. González F: Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 77: 300-305, 2012.
32. Jain SK: Hyperglicemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. J Biol Chem 264: 21340-21345, 1989.
33. Aljada A, Thusu K, Amstrong D, Nicotera T and Dandona P: Increased carbonylation of proteins in diabetes. Diabetes 44: 113A, 1995.
34. Dandona P, Thusu K, Cook S, et al: Oxidative damage to DNA in diabetes mellitus. Lancet 347: 444-445, 1996.
35. Stephens JM, Butts MD and Pekala PH: Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocytedifferentiation by tumour necrosis factor-alpha. J Mol Endocrinol 9: 61-72, 1992.
36. Zwaka TP, Hombach V and Torzewski J: C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103: 1194-1197, 2001.
37. Simó R, Barbosa-Desongles A, Sáez-Lopez C, et al: Molecular mechanism of TNFα-induced down-regulation of SHBG expression. Mol Endocrinol 26: 438-446, 2012.